Zacks Investment Research on MSN
Insulet broadens Omnipod 5 presence with commercial launch in Spain
Insulet Corporation PODD has commercially launched its Omnipod 5 Automated Insulin Delivery (AID) system and the Omnipod ...
Adults with type 2 diabetes achieved higher time in range with the next-generation Omnipod 6 automated insulin delivery ...
PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin ...
The U.S. Food and Drug Administration (FDA) has designated Insulet Corp.’s PODD recall of certain Omnipod insulin delivery ...
A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain ...
Insulet has begun shipping Omnipod 5 pods with the new algorithm to US retailers ahead of a broader software update.
Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery ...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the commercial launch of its ...
The pair of studies evaluating the technology were presented at the American Diabetes Association and simultaneously published in the Journal of Diabetes Science and Technology. The Insulet ...
What if you'd invested in Insulet (PODD) ten years ago? It may not have been easy to hold on to PODD for all that time, but ...
The news this week that the Omnipod insulin pump had finally received Medicare coverage brought cheers from diabetes advocates and physicians alike—at long last, the popular tubeless device might soon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results